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Background: Experimental data have shown that the transfusion of older red blood cell units
causes alloimmunization, but the clinical applicability of this statement has never been
properly assessed in non-sickle cell patients. It has been hypothesized that older units have
higher numbers of cytokines, increasing the risk of alloimmunization related to antigen-
presenting events. The goal of this study was to evaluate the association between the
transfusion of older red blood cell units subjected to bedside leukodepletion and alloim-
munization.
Methods: All patients submitted to transfusions of bedside leukodepletion red blood cell
units proven to have become alloimmunized in one oncologic service between 2009 and
2013 were enrolled in this study. A control group was formed by matching patients without
alloimmunization in terms of number of transfusions and medical specialty. The median
age  of transfused units, the percentage of transfused red blood cell units >14 days of storage
in  relation to fresher red cell units (≤14 days of storage) and the mean age of transfused
units  older than 14 days were compared between the groups.
Results: Alloimmunized and control groups were homogeneous regarding the most relevant
clinical variables (age, gender, type of oncological disease) and inﬂammatory background
(C-reactive protein and Karnofsky scale). The median age of transfused red blood cell units,
the  ratio of older units transfused compared to fresher units and the mean age of transfused
units older than 14 days did not differ between alloimmunized and control patients (17 vs.
17;  68/32 vs. 63.2/36.8 and 21.8 ± 7.0 vs. 21.04 ± 7.9; respectively).
Conclusion: The transfusion of older red blood cell units subjected to bedside leukodepletion
is  not a key risk factor for alloimmunization. Strategies of providing fresh red cell units
aiming to avoid alloimmunization are thus not justiﬁed.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published∗ Corresponding author at: Immunohematology Section, Avenida Dr. E
Paulo,  SP, Brazil.
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lloimmunization against red blood cell (RBC) antigens
s a late transfusion complication, the clinical predic-
ors of which in non-sickle cell patients are unclear.1,2
lloimmunization stems from the antigen-presentation pro-
ess, which is positively inﬂuenced by pro-inﬂammatory
ytokines and negatively by T regulatory cells.3 The genetics
f the patient, especially their human leukocyte anti-
en (HLA) type, plays a role in the alloimmunization
rocess,4 but other environmental factors also seem to
ontribute and have been explored little in the medical
iterature.5
The most important environmental risk factor for alloim-
unization is the recipient’s inﬂammatory background,6
hich even causes antibody development in sickle cell
atients.7 Recently it was observed that the presence of
cute chest syndrome and vaso-occlusive crises are associ-
ted with a higher risk of alloimmunization.8 Experimental
ata have demonstrated that the transfusion of older RBC
nits is also a risk factor,5 but the mechanisms for this have
ot been elucidated yet. It has been hypothesized that older
BC units may contain higher levels of pro-inﬂammatory
ytokines and products of RBC degeneration, which may
ause a burst in the antigen-presentation process and lead
o alloimmunization.5
The beneﬁcial effect of the transfusion of pre-storage
eukodepleted RBC units to reduce alloimmunization is well-
nown.9 However, whether the transfusion of older RBC units
ubjected to bedside leukodepletion is a risk factor for alloim-
unization has never been evaluated. As the accumulation
f pro-inﬂammatory interleukins increases during the stor-
ge, the infusion of older RBC units may possibly lead to a
ore  intense cytokine burst and, according to experimental
esults, to a higher risk of alloimmunization. The exact role
layed by all leukocyte-derived cytokines in the development
f alloantibodies, however, has not been deﬁned even in the
xperimental scenario.9
The goal of this case–control study was to evaluate the
ssociation between the transfusion of older RBC units sub-
ected to bedside leukodepletion and alloimmunization, hence
ustifying the prescription of fresher units as prophylaxis.
ethods
his study was approved by the Local Ethics Committee and
xempted from the application of informed consent form. All
olid cancer patients proven to have become alloimmunized
n this service (2009–2013) were enrolled. The choice to select
nly patients with non-hematological cancer was an attempt
o maximize the homogeneity of the study population. A con-
rol group was formed in parallel to the alloimmunized group
atched both in terms of the number of transfusions and
edical specialty. In this regard, every time an alloimmunized
atient was included in the study, the number of transfused
BC units until the development of the ﬁrst alloantibody
as calculated and, then, one or two non-alloimmunized
ontrol patients were added to the control group with the 1 5;3  7(5):320–323 321
same number of transfusions and a similar diagnosis. Anti-
body identiﬁcation was performed using the gel methodology
(Bio-Rad laboratories) following the manufacturer’s instruc-
tions.
All RBC units were collected in citrate-phosphate-dextrose
with adenine (CPDA-1) bags (Fresenius-Kabi) and were sub-
mitted to bedside-leukodepletion (BioR ﬁlters, Fresenius-Kabi)
before transfusion. None of the patients received phenotyped
units as a primary alloimmunization prophylaxis or received
RBC units outside this service. The patients’ inﬂammatory
background was assessed using cancer prognostic scales
capable of evaluating systemic inﬂammation (Karnofsky)1
and C-reactive protein levels (measured at inclusion in the
study).
Alloimmunized and control groups were compared in
terms of the median age of transfused units, the percentage
of older RBC units (>14 days of storage)/fresher RBC units (≤14
days of storage) transfused and the mean age of the older (>14
days of storage) transfused units. The data considered for this
comparison involved all transfused RBC units until the appear-
ance of the ﬁrst alloantibody. Considering the known risks
associated with the transfusion of older RBC units, this study
design was approved by the local Ethics Committee.
The design of the study allowed a three-day storage dif-
ference between the groups with the inclusion of 50 patients
in each arm (80% of power). All statistical analyses were per-
formed using the Statistical Package for the Social Sciences
(SPSS) software (version 18). The Mann–Whitney test was used
to compare variables with unequal distribution and the Stu-
dent t-test, to compare variables with normal distribution. A
p-value less than 0.05 was considered signiﬁcant.
Results
Fifty alloimmunized and 59 non-alloimmunized (control)
patients were enrolled in the study. The mean age of patients
was 56.74 ± 15.42 and the mean number of transfused RBC
units per patient was 4.76 ± 3.85. Groups were initially com-
pared in terms of the most relevant clinical variables (age,
gender, body mass index, diagnosis) and proved to be homo-
geneous (Table 1). The patients’ inﬂammation background,
evaluated using the Karnofsky cancer prognostic scale and C-
reactive protein levels, was also similar between the groups
(Table 1).
Median age of transfused RBC units was equal for both
groups (17 days; p-value = 0.15). The percentage of transfused
units older than 14 days was 68.0% in the alloimmunized group
and 63.3% in control group (p-value = 0.28). The mean age of
the transfused units older than 14 days was 21.8 ± 7.0 in the
alloimmunized group and 21.04 ± 7.9 in the control group (p-
value = 0.6). Table 1 compares the groups in terms of the most
important demographical and transfusion variables.
DiscussionThis study demonstrates that the transfusion of older RBC
units is not a key risk factor for alloimmunization and,
consequently, it does not support previous experimental
data. The hypothesis of a cytokine burst contributing to
322  rev bras hematol hemoter. 2 0 1 5;3  7(5):320–323
Table 1 – Comparison between alloimmunized and non-alloimmunized patients regarding clinical variables,
inﬂammatory background and age of red blood cell units transfused.
Alloimmunized group
(n = 50)
Control group
(n = 59)
p-Value
Age – years (mean ± SD) 56.2 ± 15 57.3 ± 16 0.7
Gender – female/male (%) 59.3/40.7 64/36 0.69
Diagnosis (%)
Gastrointestinal system cancer 33.9 46.9 0.21
Genitourinary system cancer 42.4 26.6
Other solid cancer 23.7 26.5
C-reactive protein – mg/L (mean) 128.8  162.4 0.36
Karnofsky Scale (median) 80  85 0.42
Age of transfused RBC units – days (median ± IQR) 17 ± 17.8 17 ± 16.7 0.15
RBC units >14 days transfused (%) 68.0 63.2 0.28
Mean age of RBC units >14 days – days (mean ± SD) 21.8 ± 7.0 21.04 ± 7.9 0.6
rRBC: red blood cell; SD: standard deviation; IQR: interquartile range.
RBC alloimmunization was not suggested by these results,
since alloimmunized and non-alloimmunized patients were
homogenous in terms of length of storage of transfused units
and the number of RBC units subjected to bedside leukodeple-
tion, which have a higher level of pro-inﬂammatory cytokines.
To the best of our knowledge, this is the ﬁrst case–control study
to evaluate the risk of alloimmunization associated with the
transfusion of older RBC units.
One previous clinical study also found no association
between older RBC units and alloimmunization, but it had
two major limitations: the use of units submitted only to
pre-storage leukodepletion, which precluded the evaluation of
leukocyte-derived cytokines, and it did not evaluate the recip-
ient inﬂammation status, an extremely important factor for
alloantibody formation.10 The present study did not ﬁnd any
association between age of the transfused unit and alloimmu-
nization, and ruled out any possible bias regarding differences
in the inﬂammatory background of participants. In contrast
to these results, there is consistent experimental data asso-
ciating the accumulation of leukocyte-derived transforming
growth factor- (TGF-)  in transfused units and lower rates
of alloimmunization.9 However, the age of storage of the RBC
units in this speciﬁc study was signiﬁcantly shorter (three days
vs. fourteen days) and only one leukocyte-derived cytokine
was evaluated, while the effect of many  others known to cause
pro-inﬂammatory stimulation were not evaluated.
It is important to highlight that this study did not exclude
the hypothesis of antibody recrudescence after transfusions
of RBC units. However, as none of the patients was trans-
fused outside the current service, this event would only be
due to pregnancy-related alloimmunization. As no antibody
with anti-D speciﬁcity was identiﬁed within the studied pop-
ulation, this bias probably had no signiﬁcant impact on the
results.
ConclusionsThe transfusion of older RBC units is not a key risk factor
for the development of RBC alloantibodies in non-sickle cell
patients. Strategies of providing fresher units as prophylaxis
for alloimmunization are therefore not justiﬁed.Conﬂicts  of  interest
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